Please login (Members) to view content or
(Nonmembers) this article.
No votes yet

Gemtuzumab Ozogamicin

Kathy Wilkinson
Carol S. Viele
CJON 2002, 6(5), 298-304 DOI: 10.1188/02.CJON.298-299

Gemtuzumab ozogamicin is indicated for the treatment of CD33 positive acute myeloid leukemia (AML) in patients 60 years of age or older in first relapse who are not candidates for cytotoxic chemotherapy. The CD33 antigen is expressed on more than 80% of patients with AML.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or